Brief: Arch Biopartners Announces Positive Results Of Dose Escalation Human Trial For Lsalt Peptide
18/04/2023 12:14
April 18 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS ANNOUNCES POSITIVE RESULTS OF DOSE
ESCALATION
HUMAN TRIAL FOR LSALT PEPTIDE
* ARCH BIOPARTNERS -RAISED MAXIMUM DAILY DOSE OF LSALT
PEPTIDE TO
20 MG/DAY IN HEALTHY, NORMAL VOLUNTEERS IN RECENTLY COMPLETED
HUMAN TRIAL IN AUSTRALIA
* ARCH BIOPARTNERS INC: IN BOTH GROUPS IN TRIAL WITH DAILY
DOSING
LSALT PEPTIDE MET PRIMARY ENDPOINTS OF SAFETY AND TOLERABILITY
* ARCH BIOPARTNERS INC - PRODUCTION OF APPROXIMATELY 10,000
LSALT
PEPTIDE DRUG PRODUCT VIALS HAS RECENTLY BEEN COMPLETED
* ARCH BIOPARTNERS- NEW VIALS UNDERGOING QUALITY CONTROL AND
QUALITY ASSURANCE PROCEDURES AT CO'S THIRD-PARTY MANUFACTURING
FACILITY IN TORONTO, CANADA
Source text for Eikon: ID:nGNX16nSbk
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide